Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3Phase NA 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Venous Thrombosis 2Pulmonary Embolism 2Hemorrhage 2Venous Thromboembolism 1Thromboembolism 1Thrombocytopenia 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1

Interventions

Dexamethasone 8Oxycodone 6Epoetin Alfa 5Propofol 4Palonosetron 4Meropenem 4Zoledronic Acid 3Vancomycin 3Sevoflurane 3Ondansetron 3Naloxone 3Everolimus 3Ciprofloxacin 3Cholecalciferol 3Ceftazidime 3Cefepime 3Calcium Dobesilate 3Bevacizumab 3Aspirin 3Aprepitant 3peginterferon alfa-2a 2edoxaban 2apixaban 2apatinib 2Vitamin B 12 2Vincristine 2Tobacco Use Cessation Devices 2Teicoplanin 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms × Dalteparin × Clear all
NCT00942968 2024-04-18

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Pfizer

Phase 4 Completed
338 enrolled 21 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡